Abstract:An innovative approach to enhance the selectivity of matrix metalloproteinase (MMP) inhibitors comprises targeting these inhibitors to catalytically required substrate binding sites (exosites) that are located outside the catalytic cleft. In MMP-2, positioning of collagen substrate molecules occurs via a unique fibronectin-like domain (CBD) that contains three distinct modular collagen binding sites. To characterize the contributions of these exosites to gelatinolysis by MMP-2, seven MMP-2 variants were generated with single, or concurrent double and triple alanine substitutions in the three fibronectin type II modules of the CBD. Circular dichroism spectroscopy verified that recombinant MMP-2 wild-type (WT) and variants had the same fold. Moreover, the MMP-2 WT and variants had the same activity on a short FRET peptide substrate that is hydrolyzed independently of CBD binding. Among single-point variants, substitution in the module 3 binding site had greatest impact on the affinity of MMP-2 for gelatin. Simultaneous substitutions in two or three CBD modules further reduced gelatin binding. The rates of gelatinolysis of MMP-2 variants were reduced by 20-40% following single-point substitutions, by 60-75% after double-point modifications, and by >90% for triple-point variants. Intriguingly, the three CBD modules contributed differentially to cleavage of dissociated α-1(I) and α-2(I) collagen chains. Importantly, kinetic analyses (k(cat)/K(m)) revealed that catalysis of a triple-helical FRET peptide substrate by MMP-2 relied primarily on the module 3 binding site. Thus, we have identified three collagen binding site residues that are essential for gelatinolysis and constitute promising targets for selective inhibition of MMP-2.

Influence of N-arylsulfonamido d-valine N-substituents on the selectivity and potency of matrix metalloproteinase inhibitors

Design, Synthesis and Preliminary Evaluation of Α-Sulfonyl Γ-(Glycinyl-amino)proline Peptidomimetics As Matrix Metalloproteinase Inhibitors.

Analysis of Matrix Metalloproteinase Triple-Helical Peptidase Activity with Substrates Incorporating Fluorogenic L- or D-amino Acids.

Design, Synthesis, and Primary Activity Evaluation of Pyrrolidine Derivatives As Matrix Metalloproteinase Inhibitors.

Dual Inhibitory Pathways of Metallofullerenol Gd@C82(OH)22 on Matrix Metalloproteinase-2: Molecular Insight into Drug-Like Nanomedicine

Covalent labeling of Matrix Metalloproteases with affinity‐based probes containing tuned reactive N‐acyl‐N‐alkyl sulfonamide cleavable linkers

Molecular Imaging Probes Based on Matrix Metalloproteinase Inhibitors (MMPIs)

Identification of collagen binding domain residues that govern catalytic activities of matrix metalloproteinase-2 (MMP-2)

Rational Design of Matrix Metalloproteinase-13 Activatable Probes for Enhanced Specificity

Synthesis of Chiral ND-322, ND-364 and ND-364 Derivatives As Selective Inhibitors of Human Gelatinase

Design, Synthesis, Evaluation and 3D-QSAR Analysis of Benzosulfonamide Benzenesulfonates As Potent and Selective Inhibitors of MMP-2

Improving Potency and Selectivity of a New Class of Non-Zn-chelating MMP-13 Inhibitors.

Design, Synthesis and Preliminary Evaluation of New Cinnamoyl Pyrrolidine Derivatives As Potent Gelatinase Inhibitors

Synthesis of Derivatives of Methyl Rosmarinate and Their Inhibitory Activities Against Matrix Metalloproteinase-1 (MMP-1)

A High Throughput Fluorogenic Substrate for Stromelysin (MMP‐3)

The selectivity of galardin and an azasugar-based hydroxamate compound for human matrix metalloproteases and bacterial metalloproteases

Synthesis and Gelatinase (MMP-2, MMP-9) Inhibitory Activities of Pyrrolidine Derivatives

Sulfonamide Derivatives Containing Dihydropyrazole Moieties Selectively and Potently Inhibit Mmp-2/Mmp-9: Design, Synthesis, Inhibitory Activity and 3D-Qsar Analysis

A Combined Molecular Modeling Study on Gelatinases and Their Potent Inhibitors

Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.

Engineered Peptide Macrocycles Can Inhibit Matrix Metalloproteinases with High Selectivity.